- Home
- AB vs RNA Comparison
AB vs RNA Comparison
Compare AB & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AB | RNA |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | 1988 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AB | RNA |
|---|---|---|
| Price | $41.61 | $71.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 20 |
| Target Price | $41.00 | ★ $69.26 |
| AVG Volume (30 Days) | 170.5K | ★ 3.0M |
| Earning Date | 10-23-2025 | 11-10-2025 |
| Dividend Yield | ★ 7.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | N/A | ★ $20,868,000.00 |
| Revenue This Year | N/A | $64.11 |
| Revenue Next Year | $8.41 | $37.25 |
| P/E Ratio | $13.70 | ★ N/A |
| Revenue Growth | N/A | ★ 106.27 |
| 52 Week Low | $32.28 | $21.51 |
| 52 Week High | $43.30 | $71.78 |
Technical Indicators
Market Signals| Indicator | AB | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 77.46 |
| Support Level | $40.80 | $71.12 |
| Resistance Level | $41.94 | $71.76 |
| Average True Range (ATR) | 0.77 | 0.43 |
| MACD | 0.18 | -0.75 |
| Stochastic Oscillator | 90.19 | 83.75 |
Price Performance
Historical ComparisonAbout AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of July 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (36% of AUM) and equity (42%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.